Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

TROPHY-U-01 Cohort 3: Sacituzumab govitecan (SG) and pembrolizumab (pembro) in patients (pts) with progression or recurrence of metastatic urothelial cancer (mUC) after platinum (PLT)-based therapy

Date

17 Sep 2020

Session

E-Poster Display

Presenters

Petros Grivas

Citation

Annals of Oncology (2020) 31 (suppl_4): S550-S550. 10.1016/annonc/annonc274

Authors

P. Grivas1, C.N. Sternberg2, N. Agarwal3, D.P. Petrylak4, S.T. Tagawa2, Q. Hong5, A. Gladden5, C. Kanwal5, T. Goswami5, Y. Loriot6

Author affiliations

  • 1 Department Of Hematology Oncology, University of Washington, 98109-4405 - Seattle/US
  • 2 Department Of Medical Oncology, Weill Cornell Medicine, 10021 - New York/US
  • 3 Division Of Oncology, Department Of Medicine, Huntsman Cancer Hospital, 84112 - Salt Lake City/US
  • 4 Department Of Medical Oncology, Yale University School of Medicine, 6520 - New heaven/US
  • 5 Clinical Development, Immunomedics, Inc., 07950 - Morris Plains/US
  • 6 Department Of Cancer Medicine, Institut de Cancérologie Gustave Roussy, 94805 - Villejuif/FR
More

Resources

Abstract 796TiP

Background

Checkpoint inhibitors (CPI) are standard therapy for pts with mUC following progression on PLT-based chemotherapy with response rates of 13–29% and limited complete responses. SG is a novel antibody-drug conjugate (ADC) comprised of a humanized monoclonal anti–Trop-2 antibody coupled to SN-38 via a unique hydrolyzable linker. Trop-2 is an epithelial cell surface antigen differentially expressed in malignant vs normal tissues, especially in UC. The phase 1/2 IMMU-132-01 trial reported an ORR of 31% with SG alone in pts with mUC, while interim data from the phase 2 TROPHY-U-01 trial cohort 1 (n=35 pts with heavily pretreated mUC who progressed on PLT, CPI) confirmed those results (ORR 29%).SG toxicity was manageable with notable AEs of neutropenia and diarrhea. An ADC with CPI showed high ORR in pts with previously untreated mUC; we hypothesize that SG with CPI may significantly benefit pts with PLT-refractory mUC.

Trial design

TROPHY-U-01 (NCT03547973) is a multi-cohort, open-label, global phase 2 trial. Cohort 3 will enroll up to 61 CPI-naïve pts with progression/recurrence after PLT-based therapy. Key inclusion criteria: ECOG PS 0 or 1, creatinine clearance ≥30 mL/min, adequate organ function. Key exclusion criteria for cohort 3: active autoimmune disease, history of interstitial lung disease. Three SG doses may be tested in combination with Pembro 200 mg in a 10-pt safety cohort lead-in to determine the recommended phase 2 dose (RP2D). A Simon 2-stage design will be conducted after RP2D identification. Stage 1 contains 21 pts (including 10 pts in the safety lead-in treated with RP2D) and up to 41 pts enrolled at the RP2D, if target clinical activity is noted at stage 1. Pts will first receive SG on days 1 and 8 with Pembro 200 mg only on day 1 of a 21-day cycle until unacceptable toxicity or disease progression. Primary objective is ORR by central review using RECIST 1.1. Secondary objectives are safety/tolerability, DOR, CBR, PFS per investigator and central review by RECIST 1.1, and investigator review by iRECIST criteria. Enrollment began in March 2020 and will continue across ∼40 sites in the USA and France.

Clinical trial identification

NCT03547973.

Editorial acknowledgement

Legal entity responsible for the study

Immunomedics, Inc.

Funding

Immunomedics, Inc.

Disclosure

P. Grivas: Honoraria (self), Honoraria (institution), Advisory/Consultancy, Speaker Bureau/Expert testimony: Genentech; Honoraria (institution): Bayer; Honoraria (self), Honoraria (institution), Advisory/Consultancy: Merck; Honoraria (institution): Mirati Therapeutics; Honoraria (institution): Oncogenex; Honoraria (self), Honoraria (institution), Advisory/Consultancy: Pfizer; Honoraria (self), Honoraria (institution), Advisory/Consultancy, Speaker Bureau/Expert testimony: Bristol-Myers Squibb; Honoraria (self), Honoraria (institution), Advisory/Consultancy: AstraZeneca; Honoraria (self), Advisory/Consultancy: Biocept; Honoraria (self), Honoraria (institution), Advisory/Consultancy: ClovisOncology; Honoraria (self), Advisory/Consultancy: EMD Serono; Honoraria (self), Advisory/Consultancy: Seattle Genetics; Honoraria (self), Advisory/Consultancy: Foundation Medicine; Honoraria (self), Advisory/Consultancy: Driver Inc.; Honoraria (self), Advisory/Consultancy: QED Therapeutics; Honoraria (self), Advisory/Consultancy: Heron Therapeutics; Honoraria (self), Advisory/Consultancy: Janssen; Honoraria (institution): Bavarian Nordic; Honoraria (institution): Immunomedics; Honoraria (institution): Debiopharm; Honoraria (self), Advisory/Consultancy: GlaxoSmithKline; Honoraria (self), Advisory/Consultancy: Roche; Honoraria (self), Advisory/Consultancy: Genzyme; Honoraria (self), Advisory/Consultancy: Exelixis. C.N. Sternberg: Honoraria (self), Advisory/Consultancy: Pfizer; Honoraria (self), Advisory/Consultancy: Merck; Honoraria (self), Advisory/Consultancy: Incyte; Honoraria (self), Advisory/Consultancy: BMS; Honoraria (self), Advisory/Consultancy: AstraZeneca; Honoraria (self), Advisory/Consultancy: UroToday. N. Agarwal: Advisory/Consultancy, Research grant/Funding (institution): Pfizer; Advisory/Consultancy, Research grant/Funding (institution): Exelixis; Advisory/Consultancy, Research grant/Funding (institution): Merck; Advisory/Consultancy: Argos; Advisory/Consultancy, Research grant/Funding (institution): EMD Serono; Advisory/Consultancy, Research grant/Funding (institution): Eisai; Advisory/Consultancy, Research grant/Funding (institution): Bayer; Advisory/Consultancy, Research grant/Funding (institution): Novartis; Advisory/Consultancy, Research grant/Funding (institution): Genentech; Advisory/Consultancy, Research grant/Funding (institution): BMS; Advisory/Consultancy, Research grant/Funding (institution): AstraZeneca; Advisory/Consultancy, Research grant/Funding (institution): Medivation; Advisory/Consultancy: Clovis; Advisory/Consultancy: Foundation One, Seattle Genetics; Advisory/Consultancy: Astellas; Advisory/Consultancy: Eli Lilly; Advisory/Consultancy: Nektar; Research grant/Funding (institution): Active Biotech; Research grant/Funding (institution): Bavarian Nordic; Research grant/Funding (institution): Calithera; Research grant/Funding (institution): Celldex; Research grant/Funding (institution): GlaxoSmithKline; Research grant/Funding (institution): Immunomedics; Research grant/Funding (institution): Janssen; Research grant/Funding (institution): New Link Genetics; Research grant/Funding (institution): Prometheus; Research grant/Funding (institution): Rexahn; Research grant/Funding (institution): Sanofi; Research grant/Funding (institution): Takeda; Research grant/Funding (institution): Tracon. D.P. Petrylak: Honoraria (self), Advisory/Consultancy, Research grant/Funding (institution): Advanced Accelerator Applications; Honoraria (self), Advisory/Consultancy, Research grant/Funding (institution): Astellas; Honoraria (self), Advisory/Consultancy: Amgen; Honoraria (self), Advisory/Consultancy, Research grant/Funding (institution): AstraZeneca; Honoraria (self), Advisory/Consultancy, Research grant/Funding (institution): Bayer; Honoraria (self), Advisory/Consultancy, Research grant/Funding (institution): BMS; Honoraria (self), Advisory/Consultancy: Bicycle Therapeutics ; Honoraria (self), Advisory/Consultancy: Boehringer Ingelheim; Honoraria (self), Advisory/Consultancy, Research grant/Funding (institution): Clovis; Honoraria (self), Advisory/Consultancy, Research grant/Funding (institution): Eli Lilly; Research grant/Funding (institution): Endocyte; Honoraria (self), Advisory/Consultancy: Exelixis; Honoraria (self), Advisory/Consultancy: Incyte; Honoraria (self), Advisory/Consultancy: Janssen; Honoraria (self), Advisory/Consultancy, Research grant/Funding (institution): Pfizer; Honoraria (self), Advisory/Consultancy: Pharmacyclics; Honoraria (self), Advisory/Consultancy, Research grant/Funding (institution): Roche Laboratories; Honoraria (self), Advisory/Consultancy, Research grant/Funding (institution): Seattle Genetics; Research grant/Funding (institution): Genentech; Honoraria (self), Advisory/Consultancy: Urogen; Research grant/Funding (institution): Innocrin; Research grant/Funding (institution): MedImmune; Research grant/Funding (institution): Merck; Research grant/Funding (institution): Novartis; Research grant/Funding (institution): Progenics; Research grant/Funding (institution): Sanofi Aventis; Shareholder/Stockholder/Stock options: Bellicum; Shareholder/Stockholder/Stock options: Tyme. S.T. Tagawa: Honoraria (self), Research grant/Funding (institution): Immunomedics. Q. Hong: Leadership role, Travel/Accommodation/Expenses, Shareholder/Stockholder/Stock options, Full/Part-time employment: Immunomedics. A. Gladden: Shareholder/Stockholder/Stock options, Full/Part-time employment: Immunomedics. C. Kanwal: Shareholder/Stockholder/Stock options, Full/Part-time employment: Immunomedics; Full/Part-time employment: Novartis. T. Goswami: Leadership role, Travel/Accommodation/Expenses, Shareholder/Stockholder/Stock options, Full/Part-time employment: Immunomedics. Y. Loriot: Honoraria (self), Research grant/Funding (institution): Roche; Honoraria (self), Research grant/Funding (institution): Astellas; Honoraria (self), Research grant/Funding (institution): Janssen; Honoraria (self), Research grant/Funding (institution): Seattle Genetics; Honoraria (self), Research grant/Funding (institution): AstraZeneca; Honoraria (self), Research grant/Funding (institution): BMS; Honoraria (self), Research grant/Funding (institution): MSD; Honoraria (self), Research grant/Funding (institution): Pfizer; Honoraria (self), Research grant/Funding (institution): Sanofi; Honoraria (self): Ipsen; Research grant/Funding (institution): Clovis; Research grant/Funding (institution): Incyte.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings